Tinea Corporis Market Research Report - Global Forecast till 2023

Global Tinea Corporis Market Research Report: By drug type (antifungals and others), by diagnosis (physical exam, imaging test, and others), by treatment (antifungal shampoos and others), by end-users (hospital pharmacies and others)—Forecast till 2023

ID: MRFR/Pharma/5373-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Global tinea corporis market is expected to rise steadily at a CAGR of 7.2% during forecast period of 2018-2023.


Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.


The global tinea corporis market is expected to see the growth in upcoming year due to entry of new drug product in market for treatment. Many key players in market are engaged in development of new drug product for tinea corporis treatment. The prevalence of tinea infection is higher in humid climatic condition. Increasing incidences of fungal diseases and increasing prevalence of various skin disorders are some of the key factors responsible for the market growth. Various other factors such as increasing awareness regarding skin infection, new drug development, are also driving the global tinea corporis market.


However certain factors that can hamper the growth of this market in near future are lack of awareness regarding fungal disease, adverse side effect due to antifungal drugs and alternative treatment plans. 


Key players:


Some of the key players in the global tinea corporis market are Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.


Intended Audience



  • Manufacturers and Suppliers

  • Hospitals and Clinics

  • Laboratories and Associations

  • Research Institutes

  • Dermatology Clinics


Market Segmentation:


Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.


Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.


Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\


Global Tinea Corporis Market by Drug Type



  • Antifungals

  • Steroids

  • Anti-Infective Combinations


Global Tinea Corporis Market, by Diagnosis



  • Physical Exam

  • Imaging Tests

    • Wood lamp (black light) examination

    • Microscopy using potassium hydroxide (KOH)

    • Fungal culture

    • Skin biopsy

    • Others




Global Tinea Corporis Market, by Treatment



  • Antifungal shampoos

  • Antifungal creams

  • Drugs

  • Others


Global Tinea Corporis Market, by End-Users



  • Hospital Pharmacies

  • Drug Stores

  • Online Pharmacies

  • Dermatology hospitals

  • Others


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.  


The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Global Tinea Corporis Market Share (%), by Region, 2017


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon


Regional Market Summary


Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region    


Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region. 


Global Tinea Corporis Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific



  • The Middle East & Africa

    • Middle East

    • Africa





Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction


2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations


Chapter 3. Research Methodology


3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation


Chapter 4. Market Dynamics


4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment


Chapter 5. Market Factor Analysis


5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis


Chapter 6. Global Tinea Corporis Market, by Drug Type


6.1 Introduction

6.2 Antifungals

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3 Steroids

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4 Anti-Infective Combinations

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023


Chapter 7. Global Tinea Corporis Market, by Diagnosis


7.1 Introduction

7.2 Physical Exam

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3 Imaging Tests

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3.1 Wood Lamp (Black Light) Examination

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3.2 Microscopy Using Potassium Hydroxide (KOH)

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3.3 Fungal Culture

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3.4 Skin Biopsy

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3.5 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 8. Global Tinea Corporis Market, by Treatmant


8.1 Introduction

8.2 Antifungal Shampoos

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.3 Antifungal Creams

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.4 Drugs

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.5 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023


Chapter 9. Global Tinea Corporis Market, by End-Users


9.1 Introduction

9.2 Hospital Pharmacies

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.3 Drug Stores

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.4 Online Pharmacies

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.5 Dermatology hospitals

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

9.6 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023


Chapter 10. Global Tinea Corporis Market, by Region


10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa


Chapter 11 Company Landscape


11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies


Chapter 12. Company Profiles


12.1 Astellas Pharma

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bayer AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Enzon Pharmaceuticals, Inc

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Galderma S.A.

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Gilead

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Novartis AG

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Pfizer Inc

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.12 Taro Pharmaceutical Industries Ltd

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.7 Teva Pharmaceutical Industries Ltd

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.12 Valeant

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13 MRFR Conclusion


13.1 Key Findings

13.1.1 From CEO’s View point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Tinea Corporis Market


Chapter 14. Appendix


LIST OF TABLES

Table 1 Global Tinea Corporis Market Synopsis, 2018–2023

Table 2 Global Tinea Corporis Market Estimates and Forecast, 2018–2023 (USD Million)

Table 3 Global Tinea Corporis Market, by Region, 2018–2023 (USD Million)

Table 4 Global Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 5 Global Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 6 Global Tinea Corporis Market, by Treatmant, 2018–2023 (USD Million)

Table 7 Global Tinea Corporis Market, by End-Users, 2018–2023 (USD Million0

Table 8 North America: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 9 North America: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 10 North America: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 11 North America: Tinea Corporis Market, by End-Users , 2018–2023 (USD Million)

Table 12 US: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 13 US: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 14 US: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 15 US: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)

Table 16 Canada: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 17 Canada: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 18 Canada: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 19 Canada: Tinea Corporis Market, by End-Users, 2018–2023 (USD Million)

Table 20 South America: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 21 South America: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 22 South America: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 23 South America: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)

Table 24 Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 25 Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 26 Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 27 Europe: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)

Table 28 Western Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 29 Western Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 30 Western Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 31 Western Europe: Tinea Corporis Market, by End-Users, 2018–2023 (USD Million)

Table 32 Eastern Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 33 Eastern Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 34 Eastern Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 35 Eastern Europe: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)

Table 36 Asia-Pacific: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)

Table 37 Asia-Pacific: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 38 Asia-Pacific: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 39 Asia-Pacific: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)

Table 40 Middle East & Africa: Tinea Corporis Market, by Drug Type, 20132-2023 (USD Million)

Table 41 Middle East & Africa: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)

Table 42 Middle East & Africa: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)

Table 43 Middle East & Africa: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Tinea Corporis Market

Figure 3 Segmentation Market Dynamics for Global Tinea Corporis Market

Figure 4 Global Tinea Corporis Market Share, by Drug Type, 2017

Figure 5 Global Tinea Corporis Market Share, by Diagnosis, 2017

Figure 6 Global Tinea Corporis Market Share, by Treatment, 2017

Figure 7 Global Tinea Corporis Market Share, by End-Users, 2017

Figure 8 Global Tinea Corporis Market Share, by Region, 2017

Figure 9 North America: Tinea Corporis Market Share, by Country, 2017

Figure 10 Europe: Tinea Corporis Market Share, by Country, 2017

Figure 11 Asia-Pacific: Tinea Corporis Market Share, by Country, 2017

Figure 12 Middle East & Africa: Tinea Corporis Market Share, by Country, 2017

Figure 13 Global Tinea Corporis Market: Company Share Analysis, 2017 (%)

Figure 14 Astellas Pharma: Key Financials

Figure 15 Astellas Pharma: Segmental Revenue

Figure 16 Astellas Pharma: Geographical Revenue

Figure 17 Bayer AG : Key Financials

Figure 18 Bayer AG : Segmental Revenue

Figure 19 Bayer AG : Geographical Revenue

Figure 20 Enzon Pharmaceuticals, Inc: Key Financials

Figure 21 Enzon Pharmaceuticals, Inc: Segmental Revenue

Figure 22 Enzon Pharmaceuticals, Inc: Geographical Revenue

Figure 23 Galderma S.A. : Key Financials

Figure 24 Galderma S.A. : Segmental Revenue

Figure 25 Galderma S.A. : Geographical Revenue

Figure 26 Gilead : Key Financials

Figure 27 Gilead : Segmental Revenue

Figure 28 Gilead . Geographical Revenue

Figure 29 Novartis AG : Key Financials

Figure 30 Novartis AG : Segmental Revenue

Figure 31 Novartis AG : Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue

Figure 35 Taro Pharmaceutical Industries Ltd: Key Financials

Figure 36 Taro Pharmaceutical Industries Ltd: Segmental Revenue

Figure 37 Taro Pharmaceutical Industries Ltd: Geographical Revenue

Figure 38 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 39 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 40 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 41 Valeant : Key Financials

Figure 42 Valeant : Segmental Revenue

Figure 43 Valeant : Geographical Revenue